Biktarvy® shows high efficacy against HIV in real-world setting
Gilead has announced interim results from the ongoing, multinational, observational single-arm, non-comparative real-world cohort BICSTaR study, designed to evaluate the antiviral effectiveness and safety profile of Biktarvy®...
November 4, 2021
by EuropeanPharmaceuticalReview
Veklury Drives 2Q Growth for Gilead
Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.
August 2, 2021
by contractpharma
Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy
Gilead Sciences has revealed new, four-year data from two Phase III studies evaluating Biktarvy for the treatment of HIV-1 in treatment-naïve adults.
March 8, 2021
by pharmatimes
China NMPA approves Biktarvy to treat HIV-1 Infection
Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks
August 18, 2019
by biospectrumasia
Biktarvy approved for the treatment of HIV-1 infection
Biktarvy approved for the treatment of HIV-1 infection
April 29, 2019
by europeanpharmaceuticalreview
Switching to Gilead's Biktarvy proves non-inferior in HIV patients
Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from a range of regimens.
March 7, 2018
by pharmafile
Gilead's Biktarvy wins megablockbuster HIV nod
and rival GlaxoSmithKline strikes back...
February 9, 2018
by fiercepharma